Anti-GD2 ADC M3554 in Advanced Solid Tumors
The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype.

Study details include:

Study Duration per participant: Approximately 4 months
Advanced Solid Tumor
DRUG: M3554
Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs), up to 4 months
Pharmacokinetic (PK) Plasma Concentrations of M3554, Cycle 1 Day 1 to Cycle 3 Day 15 and every second cycle from Cycle 4 (each cycle is of 21 days), assessed up to approximately 4 months|Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 as Assessed by Investigator, Time from randomization to planned assessment at 4 months|Duration of Response (DoR) According to RECIST Version 1.1 or RANO 2.0 as Assessed by Investigator, Time from randomization to planned assessment at 4 months|Progression-free Survival (PFS) According to RECIST Version 1.1 or RANO 2.0 as Assessed by Investigator, Time from randomization to planned assessment at 4 months|Change from Baseline in Corrected QT Interval (QTc) Interval, Pre-dose on Day 1 (baseline) up to 24 hours post-dose Day 1, Day 2, Day 5, Day 8 of Cycle 1 and Cycle 3 Day 1 (each Cycle is 21 days)
The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype.

Study details include:

Study Duration per participant: Approximately 4 months